ketamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1523	6740-88-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ketamine narketan (+/-)-Ketamine ketamine hydrochloride ketamine HCl	A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. Molecular weight: 237.73 Formula: C13H16ClNO CLOGP: 2.93 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 29.10 ALOGS: -3.71 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ketamine
narketan
(+/-)-Ketamine
ketamine hydrochloride
ketamine HCl

A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.

Molecular weight: 237.73
Formula: C13H16ClNO
CLOGP: 2.93
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 29.10
ALOGS: -3.71
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	200 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	4 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	8.41 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	19 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.47 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 19, 1970	FDA	PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	439.12	20.46	159	8634	20115	46657154
Status epilepticus	136.70	20.46	62	8731	13917	46663352
Dilatation intrahepatic duct acquired	136.08	20.46	31	8762	725	46676544
Bronchospasm	129.79	20.46	62	8731	15645	46661624
Propofol infusion syndrome	129.73	20.46	30	8763	751	46676518
Hydronephrosis	103.28	20.46	44	8749	8501	46668768
Mitochondrial DNULL mutation	101.02	20.46	20	8773	231	46677038
Biliary dilatation	95.67	20.46	29	8764	2095	46675174
Drug abuse	94.06	20.46	85	8708	63323	46613946
Respiratory depression	90.40	20.46	44	8749	11556	46665713
Intra-abdominal pressure increased	85.34	20.46	17	8776	203	46677066
Delirium	82.51	20.46	63	8730	37165	46640104
Sterile pyuria	81.21	20.46	12	8781	15	46677254
Hypercapnia	80.65	20.46	31	8762	4595	46672674
Pneumatosis	79.37	20.46	18	8775	412	46676857
Hypotension	77.84	20.46	149	8644	232440	46444829
Reduced bladder capacity	75.78	20.46	10	8783	0	46677269
Blood lactic acid increased	74.61	20.46	31	8762	5626	46671643
Drug ineffective for unapproved indication	73.39	20.46	43	8750	16370	46660899
Body tinea	70.14	20.46	19	8774	916	46676353
Blood pH decreased	69.69	20.46	24	8769	2603	46674666
Unwanted awareness during anaesthesia	68.99	20.46	15	8778	281	46676988
Gene mutation	67.43	20.46	19	8774	1061	46676208
Cardiac arrest	67.35	20.46	84	8709	90315	46586954
Blood gases abnormal	67.32	20.46	17	8776	621	46676648
Haematuria	65.17	20.46	48	8745	26810	46650459
Necrosis ischaemic	62.58	20.46	17	8776	828	46676441
Hyperaesthesia	61.81	20.46	30	8763	7826	46669443
Cystitis ulcerative	60.62	20.46	8	8785	0	46677269
Shock	59.77	20.46	42	8751	21803	46655466
Intestinal ischaemia	59.21	20.46	28	8765	6897	46670372
Cardio-respiratory arrest	56.82	20.46	63	8730	59806	46617463
Inhibitory drug interaction	55.94	20.46	19	8774	1976	46675293
Venoocclusive liver disease	55.06	20.46	23	8770	4228	46673041
Local anaesthetic systemic toxicity	54.78	20.46	13	8780	365	46676904
Infection susceptibility increased	54.30	20.46	19	8774	2160	46675109
Impaired quality of life	53.93	20.46	21	8772	3221	46674048
Airway peak pressure increased	52.53	20.46	12	8781	284	46676985
Lower urinary tract symptoms	51.14	20.46	9	8784	51	46677218
Arthralgia	50.80	20.46	5	8788	364598	46312671
Bladder hypertrophy	50.35	20.46	11	8782	211	46677058
Respiratory acidosis	49.94	20.46	24	8769	6124	46671145
Lung hyperinflation	48.55	20.46	15	8778	1154	46676115
Multiple-drug resistance	47.62	20.46	18	8775	2547	46674722
PCO2 increased	47.52	20.46	15	8778	1239	46676030
Off label use	46.64	20.46	167	8626	379674	46297595
Anaphylactic reaction	45.48	20.46	53	8740	53059	46624210
Drug ineffective	43.83	20.46	246	8547	677592	45999677
Systemic inflammatory response syndrome	43.73	20.46	21	8772	5350	46671919
Anaphylactoid shock	41.66	20.46	10	8783	295	46676974
Hallucination	41.36	20.46	49	8744	49902	46627367
Contracted bladder	41.31	20.46	6	8787	6	46677263
PO2 decreased	40.74	20.46	14	8779	1508	46675761
Tonic clonic movements	40.21	20.46	13	8780	1159	46676110
Hepatotoxicity	39.96	20.46	35	8758	24974	46652295
Glucose tolerance impaired	39.67	20.46	19	8774	4812	46672457
Agitation	38.86	20.46	50	8743	55365	46621904
Ureteral polyp	37.89	20.46	5	8788	0	46677269
Dysphoria	37.53	20.46	18	8775	4571	46672698
Oesophageal spasm	37.08	20.46	14	8779	1975	46675294
Hepatocellular injury	36.86	20.46	36	8757	29486	46647783
Infantile apnoea	36.68	20.46	11	8782	765	46676504
Ultrasound ovary abnormal	35.42	20.46	7	8786	80	46677189
Metabolic acidosis	35.38	20.46	40	8753	38740	46638529
Blood bicarbonate decreased	35.33	20.46	15	8778	2870	46674399
Diastolic hypotension	35.18	20.46	7	8786	83	46677186
Status asthmaticus	34.65	20.46	11	8782	925	46676344
Cystitis interstitial	34.58	20.46	12	8781	1330	46675939
Intensive care unit acquired weakness	34.29	20.46	10	8783	631	46676638
Rheumatoid arthritis	34.20	20.46	3	8790	240212	46437057
Foetal growth restriction	34.16	20.46	19	8774	6548	46670721
Perforation	34.08	20.46	11	8782	976	46676293
Drug tolerance	33.75	20.46	15	8778	3203	46674066
Oesophageal pain	33.74	20.46	14	8779	2529	46674740
Bladder disorder	32.83	20.46	19	8774	7059	46670210
Headache	32.02	20.46	26	8767	478326	46198943
Bladder necrosis	31.77	20.46	5	8788	12	46677257
Mucocutaneous haemorrhage	31.66	20.46	6	8787	54	46677215
Impaired work ability	31.58	20.46	23	8770	12613	46664656
Nausea	31.32	20.46	51	8742	687403	45989866
Post procedural stroke	31.18	20.46	6	8787	59	46677210
Diarrhoea	31.00	20.46	36	8757	559566	46117703
Drug interaction	30.78	20.46	96	8697	202998	46474271
Sedation	30.60	20.46	29	8764	22881	46654388
Ureteric stenosis	30.15	20.46	9	8784	616	46676653
Poor quality sleep	29.85	20.46	24	8769	15229	46662040
Biliary tract disorder	29.20	20.46	9	8784	687	46676582
Oliguria	29.10	20.46	19	8774	8740	46668529
Stress cardiomyopathy	28.62	20.46	18	8775	7766	46669503
Cholestasis	28.47	20.46	30	8763	26863	46650406
Circulatory collapse	28.17	20.46	27	8766	21597	46655672
Reversible cerebral vasoconstriction syndrome	28.13	20.46	11	8782	1706	46675563
Tachyphylaxis	28.12	20.46	7	8786	241	46677028
Cystitis	27.87	20.46	37	8756	42204	46635065
Oxygen saturation decreased	27.70	20.46	48	8745	69116	46608153
Left ventricular hypertrophy	27.58	20.46	15	8778	4948	46672321
Bone density decreased	27.25	20.46	19	8774	9733	46667536
Intensive care unit delirium	26.91	20.46	5	8788	40	46677229
Purpura	26.89	20.46	19	8774	9939	46667330
Cyanosis	26.82	20.46	23	8770	15948	46661321
Blood creatine phosphokinase increased	25.97	20.46	29	8764	27695	46649574
Depersonalisation/derealisation disorder	25.91	20.46	9	8784	1001	46676268
Tachycardia	25.18	20.46	57	8736	99565	46577704
Bradypnoea	25.09	20.46	12	8781	3027	46674242
Apnoea	24.58	20.46	16	8777	7323	46669946
Euthyroid sick syndrome	24.57	20.46	5	8788	67	46677202
Anaesthetic complication neurological	24.46	20.46	6	8787	194	46677075
Ventricular fibrillation	24.45	20.46	19	8774	11477	46665792
Arrhythmia	23.73	20.46	31	8762	34810	46642459
Ureteral disorder	22.83	20.46	6	8787	257	46677012
Bladder neck obstruction	22.73	20.46	3	8790	0	46677269
Respiratory rate increased	22.39	20.46	18	8775	11415	46665854
Platelet disorder	22.08	20.46	9	8784	1554	46675715
Product dose omission issue	21.71	20.46	3	8790	168517	46508752
Selective eating disorder	21.12	20.46	9	8784	1736	46675533
Tidal volume decreased	20.73	20.46	4	8789	40	46677229

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	282.76	20.41	113	7459	13880	29931026
Drug abuse	242.31	20.41	185	7387	81887	29863019
Cystitis ulcerative	131.12	20.41	18	7554	0	29944906
Hydronephrosis	103.93	20.41	49	7523	8934	29935972
Cystitis	82.72	20.41	41	7531	8333	29936573
Anaphylactic reaction	82.05	20.41	63	7509	27919	29916987
Bronchospasm	80.14	20.41	43	7529	10295	29934611
Biliary dilatation	73.07	20.41	20	7552	742	29944164
Biopsy bladder abnormal	72.84	20.41	10	7562	0	29944906
Cystitis interstitial	71.54	20.41	11	7561	13	29944893
Hypotension	70.77	20.41	156	7416	200409	29744497
Reduced bladder capacity	70.22	20.41	10	7562	3	29944903
Drug screen positive	69.96	20.41	30	7542	4377	29940529
Contracted bladder	63.29	20.41	10	7562	16	29944890
Drug ineffective	61.74	20.41	207	7365	340180	29604726
Delirium	59.91	20.41	62	7510	40569	29904337
Hyperaesthesia	58.96	20.41	25	7547	3548	29941358
Toxicity to various agents	55.96	20.41	132	7440	177051	29767855
Bradycardia	55.06	20.41	75	7497	65451	29879455
Respiratory depression	55.05	20.41	35	7537	11468	29933438
Cholestasis	51.81	20.41	46	7526	24904	29920002
Bladder disorder	47.13	20.41	20	7552	2843	29942063
Tachycardia	45.49	20.41	73	7499	73666	29871240
Laryngospasm	42.18	20.41	15	7557	1328	29943578
Accidental death	35.81	20.41	15	7557	2064	29942842
Status epilepticus	34.78	20.41	26	7546	11046	29933860
Lower urinary tract symptoms	34.65	20.41	8	7564	146	29944760
Diarrhoea	34.50	20.41	21	7551	334082	29610824
Delayed recovery from anaesthesia	34.44	20.41	11	7561	700	29944206
Cardiac arrest	33.46	20.41	73	7499	92777	29852129
Serotonin syndrome	33.24	20.41	31	7541	17860	29927046
Biliary tract disorder	32.71	20.41	11	7561	824	29944082
Substance abuse	32.63	20.41	21	7551	7019	29937887
Agitation	31.24	20.41	52	7520	54021	29890885
Anaphylactoid shock	31.11	20.41	9	7563	409	29944497
Hypoxia	30.34	20.41	48	7524	47806	29897100
Apnoea	29.83	20.41	19	7553	6239	29938667
Sedation	29.71	20.41	28	7544	16345	29928561
Bladder hypertrophy	29.54	20.41	8	7564	285	29944621
Hyperammonaemia	29.44	20.41	18	7554	5502	29939404
Ureteral polyp	29.13	20.41	4	7568	0	29944906
Sedation complication	28.81	20.41	10	7562	824	29944082
Drug tolerance	28.76	20.41	13	7559	2149	29942757
Drug dependence	28.70	20.41	31	7541	21264	29923642
Wolff-Parkinson-White syndrome	27.43	20.41	7	7565	197	29944709
Metabolic acidosis	27.16	20.41	40	7532	37421	29907485
Cholangiolitis	26.56	20.41	5	7567	31	29944875
Brain oedema	26.00	20.41	23	7549	12375	29932531
Fatigue	25.70	20.41	26	7546	320647	29624259
Haemodynamic instability	25.57	20.41	19	7553	7996	29936910
Nystagmus	25.35	20.41	15	7557	4323	29940583
Diabetes insipidus	25.22	20.41	12	7560	2227	29942679
Pulseless electrical activity	25.14	20.41	17	7555	6170	29938736
Ureteric stenosis	25.02	20.41	10	7562	1221	29943685
Airway complication of anaesthesia	25.01	20.41	6	7566	130	29944776
Diastolic hypertension	24.72	20.41	5	7567	47	29944859
Propofol infusion syndrome	24.67	20.41	9	7563	857	29944049
Dissociative disorder	24.55	20.41	6	7566	141	29944765
Drug ineffective for unapproved indication	24.46	20.41	21	7551	10859	29934047
Anaesthetic complication neurological	23.99	20.41	7	7565	328	29944578
Haematuria traumatic	23.71	20.41	6	7566	163	29944743
Pneumonia	23.64	20.41	30	7542	334276	29610630
Transcranial electrical motor evoked potential monitoring abnormal	23.59	20.41	4	7568	12	29944894
Urinary tract disorder	23.33	20.41	11	7561	2000	29942906
Conversion disorder	23.21	20.41	7	7565	368	29944538
Off label use	23.20	20.41	124	7448	249166	29695740
Malaise	22.71	20.41	7	7565	166955	29777951
Hepatocellular injury	22.64	20.41	30	7542	25441	29919465
Neonatal hypoxia	21.51	20.41	6	7566	239	29944667
Dyspnoea	21.46	20.41	32	7540	333263	29611643
Circulatory collapse	21.44	20.41	26	7546	20188	29924718
Behaviour disorder	21.44	20.41	11	7561	2401	29942505
Hyperthermia malignant	21.18	20.41	10	7562	1824	29943082
Drug interaction	21.15	20.41	103	7469	199465	29745441

Pharmacologic Action:

Source	Code	Description
ATC	N01AX03	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Other general anesthetics
FDA EPC	N0000175681	General Anesthetic
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:38877	intravenous anesthetics
CHEBI has role	CHEBI:50910	agente neurotoxico
CHEBI has role	CHEBI:60643	n-methyl-d-aspartate receptor antagonists
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D000700	Analgesics
MeSH PA	D000777	Anesthetics
MeSH PA	D000778	Anesthetics, Dissociative
MeSH PA	D018686	Anesthetics, Intravenous
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018691	Excitatory Amino Acid Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
FDA PE	N0000175975	General Anesthesia

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Local anesthesia	indication	386761002
Pain	off-label use	22253000
Inflammatory disease of mucous membrane	off-label use	95361005
Major depressive disorder	off-label use	370143000
Delirium	contraindication	2776000
Ocular hypertension	contraindication	4210003	DOID:9282
Alcoholism	contraindication	7200002
Myocardial infarction	contraindication	22298006	DOID:5844
Alcohol intoxication	contraindication	25702006
Hypertensive disorder	contraindication	38341003	DOID:10763
Decreased respiratory function	contraindication	80954004
Thyrotoxicosis	contraindication	90739004	DOID:7997
Acute disease of cardiovascular system	contraindication	128487001
Decompensated cardiac failure	contraindication	195111005
Cerebrovascular accident	contraindication	230690007
Raised intracranial pressure	contraindication	271719001	DOID:9428
Cerebral trauma	contraindication	275382005
Impaired cognition	contraindication	386806002
Myocardial ischemia	contraindication	414795007	DOID:3393
Hypertensive urgency	contraindication	443482000
Psychiatric Disturbance	contraindication
Cardiac Decompensation	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glutamate [NMDA] receptor	Ion channel	O15399 O60391 Q05586 Q12879 Q13224 Q14957 Q8TCU5	NMD3A_HUMAN NMD3B_HUMAN NMDE1_HUMAN NMDE2_HUMAN NMDE3_HUMAN NMDE4_HUMAN NMDZ1_HUMAN	BLOCKER	Ki	6.38	CHEMBL	CHEMBL
Glutamate receptor ionotropic AMPA	Ion channel	P42261 P42262 P42263 P48058	GRIA1_HUMAN GRIA2_HUMAN GRIA3_HUMAN GRIA4_HUMAN	OPENER			SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Glutamate NMDA receptor	Ion channel		NMD3A_RAT NMD3B_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMDZ1_RAT		IC50	6.21	CHEMBL
Acetylcholine receptor subunit alpha	Ion channel		ACHA_TORCA		IC50	5.31	CHEMBL

External reference:

ID	Source
4019796	VUID
N0000147885	NUI
D00711	KEGG_DRUG
1867-66-9	SECONDARY_CAS_RN
4018154	VANDF
4019796	VANDF
C0022614	UMLSCUI
CHEBI:6121	CHEBI
3821	PUBCHEM_CID
CHEMBL742	ChEMBL_ID
CHEMBL1714	ChEMBL_ID
D007649	MESH_DESCRIPTOR_UI
DB01221	DRUGBANK_ID
4233	IUPHAR_LIGAND_ID
2156	INN_ID
690G0D6V8H	UNII
203184	RXNORM
4944	MMSL
9883	MMSL
d00272	MMSL
001403	NDDF
004581	NDDF
31706007	SNOMEDCT_US
333847008	SNOMEDCT_US
373464007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9508	INJECTION	50 mg	INTRAMUSCULAR	ANDA	27 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9509	INJECTION	100 mg	INTRAMUSCULAR	ANDA	27 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2051	INJECTION, SOLUTION, CONCENTRATE	100 mg	INTRAMUSCULAR	ANDA	31 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2053	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAMUSCULAR	ANDA	31 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-113	INJECTION	10 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-114	INJECTION	50 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-115	INJECTION	100 mg	INTRAMUSCULAR	NDA	27 sections
KETALAR	HUMAN PRESCRIPTION DRUG LABEL	1	52584-037	INJECTION	10 mg	INTRAVENOUS	NDA	14 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-038	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAMUSCULAR	ANDA	14 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-040	INJECTION, SOLUTION, CONCENTRATE	100 mg	INTRAMUSCULAR	ANDA	14 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-108	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	14 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4399	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAMUSCULAR	ANDA	19 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	67457-001	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	22 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	67457-108	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	22 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	67457-181	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2787	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
MKO Melt Dose Pack	HUMAN PRESCRIPTION DRUG LABEL	3	71384-410	TROCHE	25 mg	SUBLINGUAL	unapproved drug other	2 sections
MKH Dose Pack	HUMAN PRESCRIPTION DRUG LABEL	3	71384-420	TROCHE	25 mg	SUBLINGUAL	unapproved drug other	2 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	72572-320	INJECTION	50 mg	INTRAMUSCULAR	ANDA	27 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	72572-321	INJECTION	100 mg	INTRAMUSCULAR	ANDA	27 sections